Impact of H1N1, H7N9, ASFV, dengue virus and COVID-19 on pharmaceutical manufacturing firms' R&D investments and economic consequences: Evidence from China

Abstract

Objective: To determine the impact of major disease epidemics on pharmaceutical manufacturing firms' Research & Development (R&D) investments and economic consequences. Methods: The sample consists of 1 582 firm-year observations from 2009 to 2022 in China, of which, 26.6% of pharmaceutical companies are involved in the diagnosis and treatment of prevalent diseases. Linear models using R&D investments, patent applications, operating performances and stock returns as dependent variables are constructed separately to examine the response of pharmaceutical companies to disease epidemics and the resulting economic consequences. Results: The prevalence of five major diseases led to a 17.5% increase in the amount of R&D investment and an 87.8% rise in the ratio of R&D investment to total assets by disease-related pharmaceutical companies, compared to unrelated pharmaceutical companies. Further evidence indicated that the patent applications for disease-related firms increased by 44.3% relative to unrelated firms after the epidemics. Though the impacts of the epidemics on firms’ operating performances were insignificant in the short term, a major disease epidemic was associated with an increase in stock returns of 67.4% and 44.6%, respectively, as measured by the capital asset pricing model and Fama-French five-factor model. Additional analysis revealed that the impacts of the epidemics on R&D investments and patent applications were more pronounced for non-state-owned enterprises than state-owned enterprises. Conclusions: This study demonstrates that disease-related pharmaceutical firms respond to the disease epidemics through increasing R&D investment. More patent applications and higher market value are the main gains from the firms’ increased investments in R&D following the epidemic, rather than the improvements of short-term operating performances.

Keywords

Exogenous demand shock / Research & Development / Disease epidemic / State-owned enterprise / Pharmaceutical manufacturing

References

[1] National Health Commission of the People's Republic of China (NHC). Regulations on emergency response to public health emergencies. [Online]. Available from:http://www.nhc.gov.cn/yjb/s3580/200804/b41369aac27847dba3e6aebccc72e2f8.shtml. [Accessed on 9 May 2003].

[2] Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect Dis 2012; 12(9):687-695.

[3] Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: A descriptive and modelling study. Lancet Infect Dis 2020; 20(7):793-802.

[4] Ayittey FK, Ayittey MK, Chiwero NB, Kamasah JS, Dzuvor C. Economic impacts of Wuhan 2019-nCoV on China and the world. J Med Virol 2020; 92(5):473-475.

[5] Ceylan RF, Ozkan B, Mulazimogullari E. Historical evidence for economic effects of COVID-19. Eur J Health Econ 2020; 21(6):817-823.

[6] Fan VY, Jamison DT, Summers LH. Pandemic risk: How large are the expected losses? B World Health Organ 2018; 96(2):129-134.

[7] Tran XH, Le TTP, Nguyen QH, Do TT, Nguyen VD, Gay CG, et al. African swine fever virus vaccine candidate ASFV-G-ΔI177L efficiently protects European and native pig breeds against circulating Vietnamese field strain. Transbound Emerg Dis 2022; 69(4):e497-e504.

[8] Graham BS. Rapid COVID-19 vaccine development. Science 2020; 368(6494):945-946.

[9] Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. Daru 2020; 28(2):799-805.

[10] Emanuel EJ, Buchanan A, Chan SY, Fabre C, Halliday D, Heath J, et al. What are the obligations of pharmaceutical companies in a global health emergency? Lancet 2021; 398(10304):1015-1020.

[11] The People’s Bank of China (PBC). Report on the implementation of China's monetary policy in the first quarter of 2020. [Online]. Available from:http://www.pbc.gov.cn/zhengcehuobisi/. [Accessed on 10 May 2020].

[12] Bernile G, Bhagwat V, Yonker S. Board diversity, firm risk, and corporate policies. J Financ Econ 2018; 127(3):588-612.

[13] Ding N, Gu L, Peng Y. Fintech, financial constraints and innovation: Evidence from China. J Corp Financ 2022; 73:102194.

[14] Zheng G, Wang S, Xu Y. Monetary stimulation, bank relationship and innovation: Evidence from China. J Bank Financ 2018; 89:237-248.

[15] Agarwal R, Gaule P. What drives innovation? Lessons from COVID-19 R&D. J Health Econ 2022; 82:102591.

[16] Yuan R, Wen W. Managerial foreign experience and corporate innovation. J Corp Financ 2018; 48:752-770.

[17] Finkelstein A. Static and dynamic effects of health policy: Evidence from the vaccine industry. Q J Econ 2004; 119(2):527-564.

[18] Saville M, Cramer JP, Downham M, Hacker A, Lurie N, Van der Veken L, et al. Delivering pandemic vaccines in 100 days-What will it take? N Engl J Med 2022; 387(2):e3.

[19] Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 2002; 359(9324):2188-2194.

[20] Blume-Kohout ME, Sood N. Market size and innovation: Effects of medicare part D on pharmaceutical research and development. J Public Econ 2013; 97:327-336.

[21] Dubois P, De Mouzon O, Scott-Morton F, Seabright P. Market size and pharmaceutical innovation. Rand J Econ 2015; 46(4):844-871.

[22] Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006; 442(7101):448-452.

[23] Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 2017; 25(6):1316-1327.

[24] Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 2015; 14(3):167-182.

[25] Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment. Lancet 2021; 397(10278):1023-1034.

[26] Lee J, Lee MK, Jeong S, Lee B, Park M. Responding to epidemic-driven demand: The role of supply channels. Int J Prod Res 2022. doi: 10.1080/00207543.2022.2118890.

[27] Meissner HC. Understanding vaccine safety and the roles of the FDA and the CDC. N Engl J Med 2022; 386(17):1638-1645.

[28] Lurie N, Keusch GT, Dzau VJ. Urgent lessons from COVID 19: Why the world needs a standing, coordinated system and sustainable financing for global research and development. Lancet 2021; 397(10280):1229-1236.

[29] Kickbusch I, Leung GM, Shattock RJ. Learning from crisis: Building resilient systems to combat future pandemics. Lancet 2021; 398(10294):e2-e6.

[30] Griliches Z, Pakes A, Hall BH. The value of patents as indicators of inventive activity. In: Dasgupta P, Stoneman P, eds. Economic policy and technical performance. Cambridge: Cambridge University Press; 1987, p. 97-124.

[31] Pandit S, Wasley CE, Zach T. The effect of research and development (R&D) inputs and outputs on the relation between the uncertainty of future operating performance and R&D expenditures. J Account Audit Fina 2011; 26(1):121-144.

[32] Ren S, Cheng Y, Hu Y, Yin C. Feeling right at home: Hometown CEOs and firm innovation. J Corp Financ 2021; 66:101815.

[33] Eberhart AC, Maxwell WF, Siddique AR. An examination of long-term abnormal stock returns and operating performance following R&D increases. J Finance 2004; 59(2):623-650.

[34] Hou K, Hsu PH, Wang S, Watanabe A, Xu Y. Corporate R&D and stock returns: International evidence. J Financ Quant Anal 2021; 57(4):1377-1408.

[35] Ciftci M, Cready WM. Scale effects of R&D as reflected in earnings and returns. J Account & Econ 2011; 52(1):62-80.

[36] Chi JD, Su X, Tang Y, Xu B. Is language an economic institution? Evidence from R&D investment. J Corp Financ 2020; 62:101578.

[37] Cumming D, Ji S, Peter R, Tarsalewska M. Market manipulation and innovation. J Bank Financ 2020; 120:105957.

[38] Chang EC, Lin TC, Ma X. Governance through trading on acquisitions of public firms. J Corp Financ 2020; 65:101764.

[39] Fama EF, French KR. A five-factor asset pricing model. J Financ Econ 2015; 116(1):1-22.

[40] Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51(6):1173-1182.

[41] Ernst H. Patent applications and subsequent changes of performance: Evidence from time-series cross-section analyses on the firm level. Res Policy 2001; 30(1):143-157.

[42] Lee M, Su HN. Technology portfolio, patent litigation probability and firm performance. In: Dundar F. Kocaoglu, Timothy R. Anderson, Tugrul U. Daim, Dilek Cetindamar Kozanoglu, Kiyoshi Niwa, Gary Perman. (eds.) Infrastructure and Service Integration: Proceedings of PICMET'14 Conference: Portland International Center for Management of Engineering and Technology (July 27-31, 2014 Kanazawa, Japan). Portland: Portland State University, 2014; p. 870-878.